Identification of amino acid residues important for ligand binding to Fas

被引:64
作者
Starling, GC
Bajorath, J
Emswiler, J
Ledbetter, JA
Aruffo, A
Kiener, PA
机构
[1] Bristol-Myers Squibb P., Seattle
[2] Bristol-Myers Squibb P., Seattle, WA 98121
关键词
RECEPTOR; CD40; MICE; SITE;
D O I
10.1084/jem.185.8.1487
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The interaction of Fas (CD95), a member of the tumor necrosis factor receptor (TNFR) family, and its ligand (FasL) triggers programmed cell death (apoptosis) and is involved in the regulation of immune responses. Although the Fas-FasL interaction is conserved across species barriers, little is currently known about the molecular details of this interaction. Our aim was to identify residues in Fas that are important for ligand binding. With the aid of a Fas molecular model, candidate amino acid residues were selected in the Fas extracellular domain 2 (D2) and D3 and subjected to serine-scanning mutagenesis to produce mutant Fas molecules in the form of Ig fusion proteins. The effects of these mutations on Fast binding was examined by measuring the ability of these proteins to inhibit Fast-mediated apoptosis of Jurkat cells and bind Fast in ELISA and BIAcore(TM) assays. Mutation of two amino acids, R86 and R87 (D2), to serine totally abolished the ability of Fas to interact with its ligand, whereas mutants K84S, L90S, E93S (D2), or H126S (D3) showed reduced binding compared with wild-type Fas. Two mutants (K78S and H95S) bound FasL comparably to wild type. Therefore, the binding of FasL involves residues in two domains that correspond to positions critical for ligand binding in other family members (TNFR and CD40) but are conserved between murine and human Fas.
引用
收藏
页码:1487 / 1492
页数:6
相关论文
共 24 条
[1]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF HUMAN 4-1BB AND ITS LIGAND [J].
ALDERSON, MR ;
SMITH, CA ;
TOUGH, TW ;
DAVISSMITH, T ;
ARMITAGE, RJ ;
FALK, B ;
ROUX, E ;
BAKER, E ;
SUTHERLAND, GR ;
DIN, WS ;
GOODWIN, RG .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (09) :2219-2227
[2]   IDENTIFICATION OF A SOURCE OF BIOLOGICALLY-ACTIVE CD40 LIGAND [J].
ARMITAGE, RJ ;
SATO, TA ;
MACDUFF, BM ;
CLIFFORD, KN ;
ALPERT, AR ;
SMITH, CA ;
FANSLOW, WC .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (08) :2071-2076
[3]   ANALYSIS OF GP39/CD40 INTERACTIONS USING MOLECULAR-MODELS AND SITE-DIRECTED MUTAGENESIS [J].
BAJORATH, J ;
MARKEN, JS ;
CHALUPNY, NJ ;
SPOON, TL ;
SIADAK, AW ;
GORDON, M ;
NOELLE, RJ ;
HOLLENBAUGH, D ;
ARUFFO, A .
BIOCHEMISTRY, 1995, 34 (31) :9884-9892
[4]   Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling [J].
Bajorath, J ;
Aruffo, A .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (01) :3-8
[5]   IDENTIFICATION OF RESIDUES ON CD40 AND ITS LIGAND WHICH ARE CRITICAL FOR THE RECEPTOR-LIGAND INTERACTION [J].
BAJORATH, J ;
CHALUPNY, NJ ;
MARKEN, JS ;
SIADAK, AW ;
SKONIER, J ;
GORDON, M ;
HOLLENBAUGH, D ;
NOELLE, RJ ;
OCHS, HD ;
ARUFFO, A .
BIOCHEMISTRY, 1995, 34 (06) :1833-1844
[6]   CRYSTAL-STRUCTURE OF THE SOLUBLE HUMAN 55 KD TNF RECEPTOR-HUMAN TNF-BETA COMPLEX - IMPLICATIONS FOR TNF RECEPTOR ACTIVATION [J].
BANNER, DW ;
DARCY, A ;
JANES, W ;
GENTZ, R ;
SCHOENFELD, HJ ;
BROGER, C ;
LOETSCHER, H ;
LESSLAUER, W .
CELL, 1993, 73 (03) :431-445
[7]   Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain [J].
Dowling, P ;
Shang, GF ;
Raval, S ;
Menonna, J ;
Cook, S ;
Husar, W .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (04) :1513-1518
[8]   Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity [J].
Drappa, J ;
Vaishnaw, AK ;
Sullivan, KE ;
Chu, JL ;
Elkon, KB .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (22) :1643-1649
[9]   INVOLVEMENT OF THE CD95 (APO-1/FAS) RECEPTOR AND LIGAND IN LIVER-DAMAGE [J].
GALLE, PR ;
HOFMANN, WJ ;
WALCZAK, H ;
SCHALLER, H ;
OTTO, G ;
STREMMEL, W ;
KRAMMER, PH ;
RUNKELL, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) :1223-1230
[10]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366